GR3036225T3 - Methods of inhibiting primary endometrial hyperplasia - Google Patents

Methods of inhibiting primary endometrial hyperplasia

Info

Publication number
GR3036225T3
GR3036225T3 GR20010401076T GR20010401076T GR3036225T3 GR 3036225 T3 GR3036225 T3 GR 3036225T3 GR 20010401076 T GR20010401076 T GR 20010401076T GR 20010401076 T GR20010401076 T GR 20010401076T GR 3036225 T3 GR3036225 T3 GR 3036225T3
Authority
GR
Greece
Prior art keywords
endometrial hyperplasia
methods
primary endometrial
inhibiting primary
inhibiting
Prior art date
Application number
GR20010401076T
Other languages
English (en)
Inventor
Robin Sharon Lee Fuchs-Young
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GR3036225T3 publication Critical patent/GR3036225T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR20010401076T 1994-08-22 2001-07-13 Methods of inhibiting primary endometrial hyperplasia GR3036225T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29412194A 1994-08-22 1994-08-22
PCT/US1995/010619 WO1996005832A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting primary endometrial hyperplasia

Publications (1)

Publication Number Publication Date
GR3036225T3 true GR3036225T3 (en) 2001-10-31

Family

ID=23131973

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401076T GR3036225T3 (en) 1994-08-22 2001-07-13 Methods of inhibiting primary endometrial hyperplasia

Country Status (20)

Country Link
EP (1) EP0771201B1 (el)
JP (1) JPH10504579A (el)
KR (1) KR970705388A (el)
AT (1) ATE200623T1 (el)
AU (1) AU706953B2 (el)
CA (1) CA2198120A1 (el)
CZ (1) CZ52297A3 (el)
DE (1) DE69520741T2 (el)
DK (1) DK0771201T3 (el)
ES (1) ES2155895T3 (el)
FI (1) FI970716A0 (el)
GR (1) GR3036225T3 (el)
HU (1) HUT76854A (el)
IL (1) IL115018A0 (el)
MX (1) MX9701359A (el)
MY (1) MY131931A (el)
NO (1) NO970787D0 (el)
PT (1) PT771201E (el)
WO (1) WO1996005832A1 (el)
ZA (1) ZA956988B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ51897A3 (en) * 1994-08-22 1997-06-11 Lilly Co Eli Inhibition method of endometrial cancer
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
DK0652004T3 (da) * 1993-10-15 2002-09-02 Lilly Co Eli Fremgangsmåder til behandling af resistente neoplasmer
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis

Also Published As

Publication number Publication date
MY131931A (en) 2007-09-28
NO970787L (no) 1997-02-20
EP0771201A1 (en) 1997-05-07
DE69520741T2 (de) 2001-10-11
EP0771201A4 (en) 1997-09-10
CA2198120A1 (en) 1996-02-29
IL115018A0 (en) 1995-12-08
DK0771201T3 (da) 2001-05-07
HUT76854A (en) 1997-12-29
FI970716A (fi) 1997-02-20
CZ52297A3 (en) 1997-08-13
MX9701359A (es) 1997-05-31
ES2155895T3 (es) 2001-06-01
KR970705388A (ko) 1997-10-09
JPH10504579A (ja) 1998-05-06
DE69520741D1 (de) 2001-05-23
AU706953B2 (en) 1999-07-01
ATE200623T1 (de) 2001-05-15
NO970787D0 (no) 1997-02-20
EP0771201B1 (en) 2001-04-18
ZA956988B (en) 1997-02-21
WO1996005832A1 (en) 1996-02-29
AU3409895A (en) 1996-03-14
FI970716A0 (fi) 1997-02-20
PT771201E (pt) 2001-07-31

Similar Documents

Publication Publication Date Title
AU7578794A (en) Methods for inhibiting endometriosis
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
SG46324A1 (en) Methods of inhibiting uterine fibrosis
IL112037A0 (en) Methods of inhibiting dysfunctional uterine bleeding
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
ZA956988B (en) Methods of inhibiting primary endometrial hyperplasia.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9706520A (es) Metodos para inhibir el cancer de ovario.

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees